REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
38.8 EUR
3.58 B EUR
11.88 B EUR
105.93 M
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Founded
1988
FIGI
BBG000HCYZV5
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
7.47%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.62%
Maturity date
Sep 15, 2030
Explore more bonds
Curated watchlists where RGO is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange REGENERON PHARMAC.DL-,001 stocks are traded under the ticker RGO.
We've gathered analysts' opinions on REGENERON PHARMAC.DL-,001 future price: according to them, RGO price has a max estimate of 1,182.58 EUR and a min estimate of 543.22 EUR. Watch RGO chart and read a more detailed REGENERON PHARMAC.DL-,001 stock forecast: see what analysts think of REGENERON PHARMAC.DL-,001 and suggest that you do with its stocks.
Yes, you can track REGENERON PHARMAC.DL-,001 financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMAC.DL-,001 is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
RGO earnings for the last quarter are 11.19 EUR per share, whereas the estimation was 10.50 EUR resulting in a 6.54% surprise. The estimated earnings for the next quarter are 10.86 EUR per share. See more details about REGENERON PHARMAC.DL-,001 earnings.
REGENERON PHARMAC.DL-,001 revenue for the last quarter amounts to 3.34 B EUR, despite the estimated figure of 3.30 B EUR. In the next quarter, revenue is expected to reach 3.62 B EUR.
RGO net income for the last quarter is 1.20 B EUR, while the quarter before that showed 1.34 B EUR of net income which accounts for −9.96% change. Track more REGENERON PHARMAC.DL-,001 financial stats to get the full picture.
No, RGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 13.45 K employees. See our rating of the largest employees — is REGENERON PHARMAC.DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMAC.DL-,001 EBITDA is 4.14 B EUR, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMAC.DL-,001 financial statements.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMAC.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.